Open AccessAutografting for patients with chronic myeloid leukemia—the hammersmith experience
Author(s) -
Mughal Tariq,
Hoyle Christine,
Goldman John M.
Publication year - 1993
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.5530110907
Subject(s) - kingdom , medical school , medicine , classics , library science , family medicine , history , biology , medical education , paleontology , computer science
Abstract The optimal approach for curing patients with chronic myeloid leukemia (CML) in chronic phase (CP) is an allogeneic bone marrow transplant BMT). However, this approach is not available to he majority of patients. Autografting, using either burged or unpurged bone marrow or peripheral blood stem cells (PBSC), could be beneficial for patients who are not eligible for BMT. Between 1984 and 1992, 21 patients with CML in CP were auto‐grafted using unmanipulated PBSC harvested either at diagnosis or thereafter. Ten of 21 patients survived at a median of 84 months following auto‐grafting (range: 12–108 months). Eleven patients lied, seven of blast transformation and four from other causes. The timing of the autograft or the harvest does not appear to have a bearing on survival.